Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000582441 | SCV000688919 | likely benign | Hereditary cancer-predisposing syndrome | 2017-11-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000637971 | SCV000759451 | likely benign | Hereditary breast ovarian cancer syndrome | 2024-08-27 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000779941 | SCV000916882 | likely benign | not specified | 2017-09-18 | criteria provided, single submitter | clinical testing | Variant summary: The BRCA2 c.517-20A>G variant involves the alteration of a non-conserved intronic nucleotide. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing, which has been confirmed by a functional study (Thery_2011). This variant is absent in 117264 control chromosomes. Taken together, this variant is classified as Likely Benign. |
Center for Genomic Medicine, |
RCV000779941 | SCV002761133 | likely benign | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing |